Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Times Interest Earned (2019 - 2022)

Keros Therapeutics filings provide 4 years of Times Interest Earned readings, the most recent being -$24126.0 for Q1 2022.

  • On a quarterly basis, Times Interest Earned fell 53.0% to -$24126.0 in Q1 2022 year-over-year; TTM through Dec 2022 was -$114790.0, a 714.5% decrease, with the full-year FY2022 number at -$114790.0, down 714.5% from a year prior.
  • Times Interest Earned hit -$24126.0 in Q1 2022 for Keros Therapeutics, down from -$4866.0 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of -$775.33 in Q3 2019 to a low of -$24126.0 in Q1 2022.
  • Median Times Interest Earned over the past 4 years was -$8444.0 (2020), compared with a mean of -$9955.0.
  • Biggest five-year swings in Times Interest Earned: crashed 723.39% in 2020 and later skyrocketed 63.39% in 2021.
  • Keros Therapeutics' Times Interest Earned stood at -$775.33 in 2019, then crashed by 1614.23% to -$13291.0 in 2020, then skyrocketed by 63.39% to -$4866.0 in 2021, then plummeted by 395.81% to -$24126.0 in 2022.
  • The last three reported values for Times Interest Earned were -$24126.0 (Q1 2022), -$4866.0 (Q4 2021), and -$20197.0 (Q3 2021) per Business Quant data.